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Objective(s): Similar characteristics of molecular pathways between cellular reprogramming events 
and tumorigenesis have been accentuated in recent years. Reprogramming-related transcription 
factors, also known as Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC), are also well-known 
oncogenes promoting cancer initiation, progression, and cellular transformation into cancer stem cells. 
Long non-coding RNAs (lncRNAs) are a major class of RNA molecules with emerging roles in stem cell 
pluripotency, cellular reprogramming, cellular transformation, and tumorigenesis. The long intergenic 
non-coding RNA ROR (lincRNA-ROR, linc-ROR) acts as a regulator of cellular reprograming through 
sponging miR-145 that normally negatively regulates the expression of the stemness factors NANOG, 
OCT4, and SOX2.  
Materials and Methods: Here, we employed a real-time PCR approach to determine the expression 
patterns of linc-ROR and its two novel spliced variants (variants 2 and 4) in esophageal squamous cell 
carcinoma (ESCC).  
Results: The quantitative real-time RT-PCR results revealed a significant up-regulation of linc-ROR 
(P=0.0098) and its variants 2 (P=0.0250) and 4 (P=0.0002) in tumor samples of ESCC, compared to 
their matched non-tumor tissues obtained from the margin of same tumors. Our data also 
demonstrated a significant up-regulation of variant 4 in high-grade tumor samples, in comparison to 
the low-grade ones (P=0.04). Moreover, the ROC curve analysis demonstrated that the variant 4 of ROR 
has a potential to discriminate between tumor and non-tumor samples (AUC=0.66, P<0.05). 
Conclusion: Our data suggest a significant up-regulation of linc-ROR and its variants 2 and 4 in ESCC 
tissue samples.  
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Introduction 
Esophageal cancer is the 6th most cause of cancer-
related death, and also it is the 8th most common 
cancer in the word (1, 2). Two main subtypes of 
esophageal malignancies, esophageal squamous cell 
carcinoma (ESCC; a common form of the cancer with 
a high incidence in the East) and adenocarcinoma 
(ADC; a rare form of the cancer with a high incidence 
in the West) have a five-year survival rate of less 
than 10%, and both of them are highly lethal (3). 
Golestan province in Northeast of Iran is one of the 
highest risk areas of ESCC form in the world. In this 
area, ESCC subtype is accounting for ~90% of all 
types of esophageal cancers (4).  
Forced ectopic expression of OCT4, SOX2, KLF4, 
and c-MYC (known as Yamanaka factors; OSKM) 
could reprogram somatic fully differentiated cells to
 
an embryonic-like or pluripotent state (5, 6). Recent 
studies indicated OSKM factors in cancer initiation 
and progression; supporting the hypothesis that 
cellular reprogramming events and tumorigenesis 
processes share similar regulatory mechanisms (7). 
In line with the hypothesis, recent evidences suggest 
that cancer could be considered as a reprogramming-
like process (8).  
Long non-coding RNAs (lncRNAs) are a new class 
of RNA molecules which comprises the most 
proportion of human transcriptome. LncRNAs have 
emerged as main players in regulating key cellular 
pathways promoting proliferation, stem cells                   
self-renewal, and cellular reprogramming events                
(9-13). Altered expression signatures of a large 
number of lncRNAs have been reported in several 
human malignancies (14, 15). The exact molecular 
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mechanisms of lncRNAs functions have not yet been 
fully elucidated. However, some of their well-known 
functions in promoting cancer progression and 
maintaining stem cell pluripotency carry out through 
association with chromatin remodeling complexes 
and transcription factors (9, 13, 16). 
Long intergenic ncRNA ROR (lincRNA-ROR, linc-
ROR) is a multi-exon lncRNA gene located in the 
genomic region of human 18q21.3. Linc-ROR was 
initially introduced by Loewer and colleagues as a 
regulator of reprogramming (ROR) in human 
induced pluripotent stem cells (iPSc) (17). OCT4, 
SOX2, and Nanog transcription factors directly bind 
to the promoter region of linc-RoR gene to induce its 
expression. Interestingly, linc-RoR shares miR-145-
response elements with that of the aforementioned 
transcription factors; and hence, it refrains 
microRNA-mediated suppression of OCT4, SOX2, and 
NANOG transcripts to maintain self-renewal and 
pluripotency status of iPSc (18).  
Here, we explored a potential expression alteration 
of linc-ROR and its newly identified splice variants (2 to 
5) in ESCC tissue samples. Since variants 3 and 5 had no 
expression levels in ESCC samples, we continued the 
work with linc-ROR variants 2 and 4. 
 
Materials and Methods 
Clinical ESCC samples 
Fresh tumor and non-tumor tissue biopsies were 
obtained from the biobanks of Gastroenterology and 
Hepatology Research Center (Golestan University                 
of Medical Sciences) and Buali (Avicenna) Research 
Institute (Mashhad University of Medical 
Sciences).The clinical samples were classified in two 
groups: 30 tumor biopsy samples obtained from 
patients with ESCC and 30 apparently normal tissue 
biopsies were taken from the margin of same tumor 
biopsies. Histopathological characteristic were 
evaluated according to the American Joint 
Committee on Cancer criteria and TNMG procedure 
for stage and grade classiﬁcation (Table 1). The 
whole experimental procedure was approved by the 
Ethics Committee of Tarbiat Modares University and 
Golestan University of Medical Sciences. Written 
consents had been also obtained from all patients 
prior to surgical removal of their tumors.   
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from both frozen tumor 
and non-tumor clinical samples, using Trizol reagent 
(Invitrogen Life Technologies, Carlsbad, CA) and 
according to the manufacturer’s instructions. To 
remove any potential contamination with DNA 
molecules, the extracted RNA was treated with a 
DNase enzyme (Takara, Japan) in an RNase-free 
condition. We then synthesized the first strand of 
complementary DNA (cDNA) by using the  
Hyperscript RT reagent Kit (GeneAll, South 
Korea) and random hexamer primers (Takara, 
Japan), as described by the manufacturers.  
 
Quantitative real-time PCR 
Bioinformatics analysis was used to design 
specific PCR primers (Figure 1A, Table 2) to amplify 
the main and the variants 2 and 4 of linc-ROR (with 
the GenBank accession numbers of NR_048536.1, 
AB844430.1, and AB844432.1, respectively), using 
Gene Runner (version 3.05), PerIPrimer (version 
1.1.21), and Oligo (version 7.56) softwares. Real Q 
plus 2x master mix Green (Ampliqon, Denmark) 
supplemented with ROX dye was used for all quanti-
tative real-time PCR reactions. As an endogenous 
control, the expression of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, NM_002046.4) 
transcript was quantified, and the expression of linc-
ROR and its variants were normalized to its 
expression level. All real-time PCR reactions were 
carried out by the ABI STEP ONE real-time PCR 
systems (Applied Biosystems, Foster City, CA) using 
the following cycling conditions: initiation at 95 C 
for 15 min, amplification for 40 cycles with 
denaturation at 95 C for 15 sec, annealing and 
extending at 63 C for 55 sec. Moreover, we 
confirmed the authenticity of the PCR products by 
melt curve analysis and direct sequencing. 
 
Statistical analysis 
All real-time PCR experiments were carried out in 
duplicates. The LinReg PCR software (version 11) 
was used to calculate the exact PCR efficiency, and 
the real-time PCR data was adjusted based on these 
efficiencies. In order to calculate the expression fold 
change of the interest genes, the expression level of 
them in each clinical sample was normalized to that 
of GAPDH gene, as an internal control. We then 
normalized the expression of candidate genes in 
tumor samples to the matched non-tumor ones (2^-
ΔΔCT method). To discriminate between tumor and
 
 
 
 
Table 1. The clinico-pathological characteristics of the patients with esophageal squamous cell carcinoma 
 
Case number Clinic-pathological Characteristics 
65.26 Age (median) 
16/14 Sex (male/female) 
1/12/2/2/9/4 Stage (I/IIA/IIB/ IIA-III/III/unknown) 
5/17/5/3 Grade (I/II/III/unknown) 
16/10/4 Location (middle/lower/unknown) 
1/1/3/1/20/1/3 Tumor invasion (T1/T1a/T2/T2a/T3/T4/unknown) 
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13/11/3/3 Regional lymph node (N0/N1/Nx/unknown) 
Table 2. The list of primers used to specifically amplify the main and variants 2 and 4 of linc-ROR as well as the internal control, GAPDH 
 
Transcript  Primer sequence PCR product (bp) 
  F 
R 
ACAAGGAGGAAAGGGCTGAC 124 
Linc-ROR  TTCTGGAAGCTAAGTGCACATG  
  F 
R 
AAGCAGCTGTGACCTGGC 179 
AB844430 
 variant 2 
 TCTGGCACCTAGCATAGCAC 
 
  F 
R 
CAGCCCAAAAATATCGTCAGAGT 265 
AB844432 
 variant 4 
 TCTTACTTAGCGACAATGCCATC 
 
  F 
R 
ATGGGGAAGGTGAAGGTCG 108 
GAPDH  GGGGTCATTGATGGCAACAATA  
 
 
 
Figure 1. A) A representative schematic view of the genomic 
organization of linc-ROR and its spliced variants 2 and 4. The 
location of the forward and reverse primers used to amplify 
specifically each transcript is indicated with different set of 
arrows. B) Expression alteration of linc-ROR, and its splice 
variants 2 and 4 in ESCC tumor samples. The relative expression 
levels of linc-ROR and its splice variants 2 and 4are represented in 
ESCC tumors vs. their matched non-tumor samples obtained from 
the same patients. An up-regulation of linc-ROR, and its splice 
variants in ESCC tumor vs non-tumor samples is evident.                           
C) Relative gene expressions in high and low grades esophageal 
tumors. The red and blue boxes represent high grade (GIII) and 
low grade (GI and GII) tumor samples, respectively. Note that 
there is a significant up-regulation just for the linc-ROR variant 4 
in high-grade tumors of ESCC  
ESCC: esophageal squamous cell carcinoma 
 
non-tumor clinical samples, as well as between 
different grades of tumor samples, receiver 
operating characteristic (ROC) curve analysis was 
plotted by Graphpad Prisom (version 5.0.0.288).  
 
Results  
Up-regulation of linc-ROR in ESCC tissue samples 
To quantify linc-ROR variants transcripts in ESCC 
samples, we designed specific primers on regions 
that were unique for each RNA transcript                     
(Figure 1A). Our quantitative real-time RT-PCR data 
demonstrated a significant up-regulation of linc-ROR 
in tumor samples of ESCC, compared to the marginal 
non-tumor tissues obtained from the same patients 
(fold change 1/61, P=0.0098, Figure 1B). Next, we 
investigated a potential association between linc-
ROR expression and the grade of malignancy of ESCC  
 
tumors. The data analysis, however, failed to show 
any association between the expression level of linc-
ROR with the grade of malignancy of samples (Figure 
2C). Moreover, there was no statistically significant 
difference of linc-ROR expression in tumor samples 
between different genders (data not shown).  
 
Up-regulation of linc-ROR variants 2 and 4 in ESCC 
tissue samples 
We next quantified the expression patterns of                
two novel variants of linc-ROR, variants 2 and 4, in ES 
CC tissue samples. Specific primers were designed in 
regions that were unique for each transcript                   
(Figure 1A). The quantitative real-time PCR data 
revealed a significant up-regulation of variant 2 (fold 
change 1/67, P=0.025) and variant 4 (fold change 2/65, 
P=0.0002) in tumor specimens, in comparison to their 
paired non-tumor samples (Figure 1B). The data was 
unable to find any association between the expression 
levels of variant 2 with the grade of malignancy of the 
tumors (Figure 2B). In contrast, variant 4 had a 
significantly higher expression level in high grade (GIII) 
tumors, compared to the low grade (GI and GII) ones 
(P=0.04. Figure 1B). Moreover, there was no 
statistically significant difference between expression 
alteration of the linc-ROR variants 2 and 4 and the 
gender of patients (data not shown).  
 
 
 
 
 
 
Figure 2.  Analyzing the sensitivity and specificity of linc-ROR 
variants, as potential tumor markers of ESCC. ROC curve analysis 
demonstrated only a moderate sensitivity and specificity of linc-
ROR spliced variant 4’sexpression level to discriminate between 
tumor and non-tumor states of ESCC tissue samples. Similarly, 
Area Under the Curve (AUC) was statistically significant only for 
variant 4 (AUC=0.65, P=0.049). An AUC>70 is considered as a good 
index for a biomarker with a high ability to correctly classify 
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tumor and non-tumor groups of samples. On the other hand, the 
ROC curve analysis failed to discriminate between high and low 
grade ESCC tumor samples 
ESCC: esophageal squamous cell carcinoma 
The expression level of linc-ROR spliced variant 4 
could discriminate between tumor and non-tumor 
states of ESCC samples 
We performed ROC curve analysis to evaluate the 
suitability of linc-ROR and its variants (2 and 4) 
expression levels to discriminate between tumor and 
non-tumor states of ESCC clinical samples. The data 
represent AUC=0.512 (P>0.05), AUC=0.522 (P>0.05), 
and AUC=0.656 (P=0.049) for linc-ROR, variant 2, and 
variant 4, respectively (Figure 2). In contrast to linc-
ROR and variant 2, variant 4 showed a better suitability 
to classify tumor and non-tumor samples of esophagus. 
However, its AUC score, slightly fell below the score 
needed for a good biomarker (AUC>70). Moreover, in 
evaluation of different grades of malignancy and 
expression of the linc-ROR and its variants, ROC curve 
analysis failed to discriminate high and low grades 
tumor samples (data not shown).  
 
Discussion 
Up-regulation of several lncRNAs including 
HOTAIR, MALAT1, PCAT-1, UCA1, and SOX2OT have 
been reported in ESCC (19-24). Based on numerous 
similarities between molecular pathways of 
tumorigenesis and reprogramming events and the 
fact that linc-ROR promotes cellular reprogramming, 
we hypothesized that this non-coding RNA could 
have a part in cancer initiation and/or progression 
processes. For this reason, we aimed to investigate 
its expression pattern in ESSC clinical specimens. 
Furthermore, we examined a potential correlation 
between its expression pattern and histopathological 
characteristics of the ESCC tumor samples. 
Our data revealed that linc-ROR and its spliced 
variants 2 and 4 were up-regulated in ESCC tumors 
samples, compared to their corresponding non-
tumors ones obtained from the margin of same 
tumors. Moreover, our data demonstrated a 
signiﬁcant up-regulation of variant 4 (but neither 
linc-ROR nor variant 2) in high-grade ESCC tumors, 
suggesting a potential role for variant 4 in ESCC 
tumor progression. Despite a statistically significant 
up-regulation of the main and spliced variants of 
linc-ROR in ESCC tissue samples, the  data  obtained  
from  ROC curve analysis demonstrated that only 
variant 4 has a moderate sensitivity and specificity in  
discriminating  between  tumor  and  non-tumor 
ESCC samples. 
Our data on elevated levels of linc-ROR transcripts 
in ESCC samples, is in agreement with recent studies 
reporting an up-regulation of linc-ROR in several other 
somatic cancers including breast cancer and 
hepatocellular carcinoma (25, 26). Overexpression of 
linc-ROR caused an epithelial to mesenchymal 
transition (EMT) process in immortalized human 
mammary epithelial cells, probably through preventing 
the degradation of miR-205 target genes, such as the 
inducer of EMT known as ZEB2 (25). Linc-ROR is also 
implicated in breast cancer cells metastasis, and the 
induction and maintenance of stemness properties to 
the pluripotent and cancer stem cells (25). Linc-ROR 
was also highly up-regulated in hepatocellular cancer 
cells. The extracellular linc-ROR derived from 
hepatocellular tumor cells could modulate the 
chemosensitivity of the tumor cells (26). Moreover, 
human linc-RoR is a strong negative regulator of P53 
transcription factor, in response to DNA damage. In 
contrast to MDM2 that causes P53 degradation, linc-
ROR suppresses P53 translation, and p53-mediated cell 
cycle arrest and apoptosis (27). 
In contrast to the aforementioned studies claiming 
an up-regulation of linc-ROR in some cancers, Feng et al. 
reported a significant down-regulation of linc-ROR 
expression in glioma tumors. Accordingly, ectopic 
expression of linc-ROR diminished cell proliferation, 
inhibited KLF4 expression, and decreased the capacity 
of tumorosphere formation in U87 glioma cell line. The 
latter findings suggested that linc-ROR may act as a 
tumor suppressor gene in glioma (28).  
 
Conclusion  
Our data highlighted the up-regulation of linc-ROR 
and its splice variants 2 and 4 in ESCC. Our data also 
propose the existence of more similarities in molecular 
pathways common between tumorigenesis and 
reprogramming events. Altogether, our data suggest 
that linc-ROR transcripts might have a potential role in 
tumor initiation and/or progression of esophagus 
cancer. However, this conclusion needs further 
functional analysis for experimental validation. 
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